Johnson & Johnson MedTech said its investigational Ottava robotic surgical system met its primary safety and efficacy endpoints through 30 days in a study of Roux-en-Y gastric bypass surgery, generating fresh data to support the company's pending de novo submission to the U.S. Food and Drug Administration.
The IDE study in detail
Patients enrolled in the Investigational Device Exemption trial lost an average of 30 pounds in the first 30 days post-operation, with safety outcomes consistent with established laparoscopic and competing robotic approaches. J&J said the dataset has now been incorporated into the supporting package for the FDA submission it filed earlier this year for de novo authorisation in general surgery.
Why Ottava matters
Ottava is J&J's long-incubated push to challenge Intuitive Surgical's da Vinci franchise. The system uses four arms mounted in the operating-room table itself – freeing floor space and giving the surgical team better access to the patient – combined with the company's Polyphonic digital ecosystem for analytics. Bariatric surgery is a strategically important wedge because volumes are growing as GLP-1 drugs reshape the obesity-care pathway and many surgeons want robotics for complex anastomoses.
Where it sits in a busy market
The Ottava data lands as CMR Surgical brings Versius Plus to the U.S. and as Microsure clears Europe with MUSA-3, intensifying the field beyond Intuitive's near-monopoly. J&J also continues to push toward general and gynaecologic indications, with planned submissions to follow over the next 12-18 months.
What's next
The company has not specified a target FDA decision date but is expected to begin commercial readiness work, including surgeon training and capital-equipment financing programs, in parallel with the review.
Reporting based on coverage from MedTech Dive, MassDevice and Johnson & Johnson investor materials.